IRLAB Therapeutics AB (OSTO:IRLAB A) Moat Score: 0/10 (As of Jul. 01, 2026)


OSTO:IRLAB A IRLAB Therapeutics AB OSTO:IRLAB A
31 GF Score
Price kr1.24
GF Value kr11.76
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is IRLAB Therapeutics AB Moat Score?

IRLAB Therapeutics AB has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

IRLAB Therapeutics AB has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes IRLAB Therapeutics AB might have No Moat - No discernible moat.

IRLAB Therapeutics AB  (OSTO:IRLAB A) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

IRLAB Therapeutics AB Moat Score Related Terms

OSTO:IRLAB A
31GF Score
IRLAB Therapeutics AB OSTO:IRLAB A
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is IRLAB Therapeutics AB (OSTO:IRLAB A) Overvalued in 2026?

Based on GuruFocus' analysis, IRLAB Therapeutics AB stock appears to be undervalued. The current stock price of kr1.24 is trading 89.5% below its estimated GF Value™ of kr11.76. GuruFocus considers IRLAB Therapeutics AB to be Possible Value Trap.

Key valuation signals for OSTO:IRLAB A:

  • Moat Score: 0
  • GF Value™: kr11.76 vs. price of kr1.24 (89.5% below fair value)
  • GF Score™: 31/100 with 6 warning signs

No single metric tells the full story. See the OSTO:IRLAB A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IRLAB Therapeutics AB Business Description

Other Exchanges 6IRA:Germany
Address Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds that aims to offer improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
31GF Score

Get the complete analysis for OSTO:IRLAB A

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.24
Price
kr11.76
GF Value